Wang L, Weinshilboum R
Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
Oncogene. 2006 Mar 13;25(11):1629-38. doi: 10.1038/sj.onc.1209372.
The thiopurine S-methyltransferase (TPMT) genetic polymorphism is one of the most 'mature' examples in pharmacogenetics. That is true because of its importance clinically for the individualization of thiopurine drug therapy and also because TPMT has provided novel insights into molecular mechanisms responsible for the functional effects of common genetic polymorphisms. This review will summarize the development of our understanding of the role of inheritance in the regulation of TPMT as well as the clinical implications of that genetic regulation. It will also summarize recent studies in which TPMT pharmacogenetics has enhanced our understanding of molecular mechanisms by which common polymorphisms influence or alter function. TPMT pharmacogenetics highlights the potential clinical importance of the translation of pharmacogenetics from bench to bedside, the potential for basic pharmacogenetic research to provide insight into mechanisms by which genetic polymorphisms can alter function, and the challenges associated with the achievement of both of those goals.
硫嘌呤甲基转移酶(TPMT)基因多态性是药物遗传学中最“成熟”的例子之一。之所以如此,是因为它在临床上对于硫嘌呤药物治疗的个体化具有重要意义,还因为TPMT为常见基因多态性的功能效应所涉及的分子机制提供了新的见解。本综述将总结我们对遗传在TPMT调节中的作用的理解发展,以及该基因调节的临床意义。它还将总结近期的研究,其中TPMT药物遗传学增强了我们对常见多态性影响或改变功能的分子机制的理解。TPMT药物遗传学突出了药物遗传学从实验室到临床应用的潜在临床重要性、基础药物遗传学研究为深入了解基因多态性改变功能的机制提供见解的潜力,以及实现这两个目标所面临的挑战。